A novel screening method to assess developability of antibody-like molecules

mAbs

Volumn 7, Issue 4, 2015, Pages 752-758

  Kohli, Neeraj ^a   Jain, Nidhi ^a   Geddie, Melissa L ^a   Razlog, Maja ^a   Xu, Lihui ^a   Lugovskoy, Alexey A ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

Colloidal stability; Developability; Size exclusion chromatography; Standup monolayer absorption chromatography; Zenix column

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; CENTRIFUGATION; CHROMATOGRAPHY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHOBICITY; ION PAIR CHROMATOGRAPHY; PROTEIN AGGREGATION; SIZE EXCLUSION CHROMATOGRAPHY; BIOSYNTHESIS; CELL LINE; CHEMISTRY; GENETICS; PH;

ANTIBODIES, MONOCLONAL; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROGEN-ION CONCENTRATION; RECOMBINANT PROTEINS;

EID: 84983657095     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1048410     Document Type: Article

References (32)

1. Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, De Haan L. Monoclonal antibody therapeutics:history and future. Curr Opin Pharmacol 2012; 12:615-22
2. Maggon K. Monoclonal antibody "gold rush". Curr Med Chem 2007; 14:1978-87; PMID:17691940; http://dx.doi.org/10.2174/092986707781368504
3. Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene 2003; 22:9097-106; PMID:14663488; http://dx.doi.org/10.1038/sj.onc.1207104
4. Von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003; 54:343-69; PMID:12525678; http://dx.doi.org/10.1146/annurev.med.54.101601.152442
5. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science [Internet] 2013; 341:1192-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24031011; http://dx.doi.org/10.1126/science.1241145
6. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1:755-68; PMID:17406305; http://dx.doi.org/10.1038/nprot.2006.94
7. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553-7; PMID:9181578; http:// dx.doi.org/10.1038/nbt0697-553
8. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105-16; PMID:16151404; http://dx.doi.org/10.1038/nbt1126
9. Tiller T. Single B cell antibody technologies. N Biotechnol 2011; 28:453-7; PMID:21473940; http://dx. doi.org/10.1016/j.nbt.2011.03.014
10. FilpulaD. Antibody engineering and modification technologies. Biomol Eng 2007; 24:201-15; PMID:17466589; http://dx.doi.org/10.1016/j.bioeng.2007.03.004
11. Lee EC, Owen M. The application of transgenic mice for therapeutic antibody discovery. Methods Mol Biol 2012; 901:137-48; PMID:22723098; http://dx.doi. org/10.1007/978-1-61779-931-0_8
12. Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, BaumJ, Johnson B, Tang J, Schoeberl B, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs 2013; 5:237-54; PMID:23392215; http://dx.doi.org/10.4161/mabs.23363
13. Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration. J Pharm Sci 2007; 96:1504-17; PMID:17387698; http://dx.doi.org/10.1002/jps.20508
14. Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 2010; 99:1152-68; PMID:19705420; http://dx.doi.org/10.1002/jps.21898
15. Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JMR, Shire SJ, Gokarn YR. Weak interactions govern the viscosity of concentrated antibody solutions:high-throughput analysis using the diffusion interaction parameter. Biophys J 2012; 103:69-78; PMID:22828333; http://dx.doi.org/10.1016/j.bpj.2012.04.047
16. Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 2011; 16:3675-700; PMID:21540796; http://dx.doi.org/10.3390/molecules16053675
17. Saxena V, Panicucci R, Joshi Y, Garad S. Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates. J Pharm Sci 2009; 98:1962-79; PMID:18855914; http://dx.doi.org/10.1002/jps.21592
18. Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs 2013; 5:787-94; PMID:23883920; http://dx.doi.org/10.4161/mabs.25269
19. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 2010; 114:6614-24; PMID:20411962; http://dx.doi.org/10.1021/ jp911706q
20. Hawe A, Kasper JC, Friess W, Jiskoot W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 2009; 38:79-87; PMID:19540340; http://dx.doi.org/10.1016/j.ejps.2009.06.001
21. Jacobs SA, Wu SJ, Feng Y, Bethea D, O’Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 2010; 27:65-71; PMID:19911257; http://dx.doi.org/10.1007/s11095-009-0007-z
22. Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs 2014; 6:483-92; PMID:24492294; http://dx.doi.org/10.4161/mabs.27431
23. Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm 2013; 10:1322-31; PMID:23383873; http://dx.doi. org/10.1021/mp300524x
24. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61
25. Nieba L, Honegger A, Krebber C, Plückthun A. Disrupting the hydrophobic patches at the antibody variable/ constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 1997; 10:435-44; PMID:9194169; http://dx.doi.org/10.1093/protein/10.4.435
26. Spencer S, Bethea D, Raju TS, Giles-Komar J, Feng Y. Solubility evaluation of murine hybridoma antibodies. MAbs 2012; 4:319-25; PMID:22531448; http://dx. doi.org/10.4161/mabs.19869
27. Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ. Highthroughput thermal scanning: a general, rapid dyebinding thermal shift screen for protein engineering. J Am Chem Soc 2009; 131:3794-5; PMID:19292479; http://dx.doi.org/10.1021/ja8049063
28. Saito S, Hasegawa J, Kobayashi N, Kishi N, Uchiyama S, Fukui K. Behavior of monoclonal antibodies: relation between the second virial coefficient (B 2) at low concentrations and aggregation propensity and viscosity at high concentrations. Pharm Res 2012; 29:397-410; PMID:21853361; http://dx.doi.org/10.1007/s11095-011-0563-x
29. Tessier PM, Lenhoff AM, Sandler SI. Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography. Biophys J 2002; 82:1620-31; PMID:11867474; http://dx.doi.org/10.1016/S0006-3495(02)75513-6
30. Einaga Y, Abe F, Yamakawa H. Light-scattering method of determining the 2nd virial-coefficient for simple molecules and oligomers. J Phys Chem 1992; 96:3948-53; http://dx.doi.org/10.1021/j100189a008
31. Kheddo P, Tracka M, Armer J, Dearman RJ, Uddin S, Van Der Walle CF, Golovanov AP. The effect of arginine glutamate on the stability of monoclonal antibodies in solution. Int J Pharm 2014; 473:126-33; PMID:24992318; http://dx.doi.org/10.1016/j.ijpharm.2014.06.053
32. Goldberg DS, Bishop SM, Shah AU, Sathish HA. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J Pharm Sci [Internet] 2010; 100:1306-15. Available from: http://www.ncbi.nlm. nih.gov/pubmed/20960568; http://dx.doi.org/10.1002/jps.22371